

Leukaemia Section

Short Communication

t(9;21)(p22;q22)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers; CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: December 2007

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/t0921p22q22ID1304.html>

DOI: 10.4267/2042/44394

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2009 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics and pathology

Disease

Treatment related acute myeloid leukaemia (t-AML)

Phenotype/cell stem origin

Only 2 cases to date, a M4-AML and a case with no data.

Clinics

A 7 year old boy presented with M4-AML 67 months after treatment of a T-ALL with epipodo-phyllotoxins.

Prognosis

No data.

Genetics

Note

It is likely that RUNX1 was involved in the translocation. RUNX1, also called AML1 or CBFA2, is a transcription factor, critical regulator of hematopoietic-cell development, involved in many de novo and treatment related leukaemias.

Cytogenetics

Additional anomalies

The patient also had a t(11;19)(q23;p13) and a complex karyotype with other (non-recurrent) anomalies.

References

Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. *N Engl J Med.* 1991 Dec 12;325(24):1682-7

Slovak ML, Bedell V, Popplewell L, Arber DA, Schoch C, Slater R. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. *Genes Chromosomes Cancer.* 2002 Apr;33(4):379-94

This article should be referenced as such:

Huret JL. t(9;21)(p22;q22). *Atlas Genet Cytogenet Oncol Haematol.* 2009; 13(1):83.